What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

ImmunityBio (IBRX) Gains Technical Strength with Golden Cross After 41.9% Surge

ImmunityBio (IBRX) shares are showing further signs of strength following a 41.9% surge driven by positive earnings revisions. Technical analysis now confirms a 'Golden Cross' pattern, signaling a sustained long-term upward trend for the biotech firm. The stock is currently trading approximately 170% above its 200-day moving average, highlighting extreme price momentum and robust investor demand. This technical validation complements the fundamental boost from Zacks' upward earnings estimate revisions reported earlier. The combination of fundamental and technical indicators suggests a robust bullish outlook for the company's market performance. Investors are closely monitoring the stock's ability to maintain this trajectory given the significant deviation from its long-term moving average. This technical milestone reinforces the overall positive sentiment surrounding the stock's future potential.

ImmunityBio (IBRX) Gains Technical Strength with Golden Cross After 41.9% Surge

Version History

Instruments